Skip to main
  1. Stocks
  2. Collegium Pharmaceutical
  3. Forecast
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical is well positioned by a growing ADHD franchise and a resilient pain portfolio, with Jornay PM sales of $51.9M, up 24% year over year, and total ADHD revenue of $78.4M, up 33% sequentially. Its expanded 190-rep salesforce, broader formulary access, and successful Azstarys integration support the view that script growth can accelerate while management guides to 2026 Jornay PM sales of $190M-$200M and Azstarys sales of $65M-$75M. The company also appears undervalued relative to its cash-generating pain assets, as Belbuca produced $57.7M in revenue and patent protection through 2032 may delay generic erosion, helping fund share repurchases and future business development.

Bears say

Collegium Pharmaceutical is facing a deteriorating fundamental setup because its pain franchise is under pressure from generic competition, lower net pricing on the Hikma authorized generics, and shrinking opioid script volumes, with the total Nucynta franchise falling to $35.2M in 2Q26, down 24% year over year. Management also cut 2026 revenue guidance by $40M for Nucynta, while Belbuca still carries meaningful uncertainty around potential generic entry beginning in 2027, creating a difficult outlook for a business that relies on exclusivity and reimbursement support. Although Jornay PM and Azstarys offer longer-term growth visibility, the company still faces commercialization, REMS, and third-party supply risks, and those newer assets may not offset erosion across the core pain portfolio.

Collegium Pharmaceutical (COLL) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction

Get the latest Collegium Pharmaceutical (COLL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Collegium Pharmaceutical (COLL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 7 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction

Get the latest Collegium Pharmaceutical (COLL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Collegium Pharmaceutical (COLL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover COLL stock data and trends